Clinical trial / 2007
Xuezhikang, an extract of cholestin, reduced CHD events and all-cause mortality in type 2 diabetes patients with coronary heart disease.
In a subgroup analysis of the CCSPS, 591 diabetic patients with coronary heart disease were randomized to receive xuezhikang (n=306) or placebo (n=285) over an average follow-up of 4 years. CHD events occurred in 9.2% of the xuezhikang group versus 18.6% of the placebo group, reflecting a 50.8% risk reduction (P<0.001). Xuezhikang significantly lowered the risk of CHD death by 44.1% (6.9% vs. 12.3%, P<0.05) and all-cause death by 44.1% (27 vs. 45 deaths, P<0.01).
- Study type
- Randomized controlled trial (subgroup analysis)
- Who was studied
- 591 patients with type 2 diabetes and coronary heart disease
- What was measured
- Coronary heart disease (CHD) events, CHD death, and all-cause mortality
THE PAPER
Xuezhikang, an extract of cholestin, reduces cardiovascular events in type 2 diabetes patients with coronary heart disease: subgroup analysis of patients with type 2 diabetes from China coronary secondary prevention study (CCSPS).
Zhao SP, Lu ZL, Du BM, Chen Z, Wu YF, Yu XH, Zhao YC, Liu L, Ye HJ, Wu ZH, China Coronary Secondary Prevention Study (CCSPS). J Cardiovasc Pharmacol, 2007.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.